REGENXBIO Inc. is the leading next-generation AAV gene therapy company, developing a new class of personalized therapies based on its proprietary NAV(R) Technology platform for a range of severe diseases with serious unmet needs. NAV Technology includes novel AAV vectors AAV7, AAV8, AAV9, and AAVrh10. REGENXBIO has enabled leading global partners including Baxter Healthcare, Fondazione Telethon, Audentes Therapeutics, Lysogene, Esteve, AveXis, AAVLife and Voyager Therapeutics to use its NAV Technology. In addition, together with Fidelity Biosciences, REGENXBIO formed Dimension Therapeutics, a company focused on the development and commercialization of NAV-based gene therapies for liver-directed rare diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/21/15 | $30,000,000 | Series C |
Brookside Capital Deerfield Management Company, L.P. FoxKiser Venrock | undisclosed |
| 05/20/15 | $70,500,000 | Series D |
Brookside Capital Cormorant Asset Management Deerfield Management Company, L.P. Foresite Capital Janus Capital Jennison Associates Perceptive Advisors QVT Financial RTW Investments Tourbillon Global Ventures Venrock Vivo Ventures | undisclosed |
